<DOC>
	<DOCNO>NCT02135536</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability , activity extend treatment NGM282 patient Primary Biliary Cirrhosis .</brief_summary>
	<brief_title>Phase 2b Study NGM282 Extended Treatment Patients With Primary Biliary Cirrhosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Liver Cirrhosis , Biliary</mesh_term>
	<criteria>Completion NGM 130103 Males female , 18 75 year age , inclusive PBC Diagnosis consistent AASLD EASL guideline Stable dose UDCA Chronic liver disease nonPBC etiology Evidence clinically significant hepatic decompensation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>